Massachusetts By the Numbers
Massachusetts is home to a biotechnology cluster that is second to none. Complementing its outstanding biopharmaceutical companies are 122 colleges and universities - over 40 of which offer advanced degrees in the life sciences, the top five National Institutes of Health-funded hospitals in the nation, and the highest educated workforce in the U.S. that offers unparalleled skills and productivity to employers.
The latest MassBio 2012 Industry Snapshot can be downloaded here: 2012 Industry Snapshot
There are more than 500 biotech and pharma companies located in Massachusetts (MassBio, 2011); 314 of these companies are drug development companies. (Evaluate Pharma, 2012)
As of August 2012, there were 955 drugs in development, from research project to pending approval stage, in Massachusetts. These figures do not include the substantial number of drugs being developed in Massachusetts by companies with headquarters outside of the state.
Pipeline by Therapeutic Area:
Funding & Capital
Massachusetts received $2.5 billion in NIH funding for basic research in Fiscal Year 2011. Massachusetts researchers receive over 11% of all NIH research funds.
Massachusetts is home to the TOP 5 NIH funded hospitals in the U.S. (FY 2011)*:
1. Massachusetts General Hospital ($324,620,848)
2. Brigham and Women's Hospital ($288,436,449)
3. Beth Israel Deaconess Medical Center ($131,304,171)
4. Dana-Farber Cancer Institute ($130,136,550)
5. Children's Hospital Boston ($118,512,044)
*National Institutes of Health, 2012
On a per capita basis, Massachusetts receives over twice as much NIH funding (FY 2010) as the next closest state.
Massachusetts biotechnology companies received a record $1.071 billion in Venture Capital financings in 2011.
2010 PricewaterhouseCoopers, National Venture Capital Association, MoneyTreeTM Report, Historical Trend Data.
Massachusetts biotech companies received 23% of all U.S. venture capital for biotech in 2011.
Massachusetts has the highest educated workforce in the United States. It ranks 1st in the nation in percentage of residents with a bachelors degree or higher. Its elementary and secondary students perform best in the nation on national assessments.
There are 53,253 biopharma employees in Massachusetts (2011) and the companies employing those workers are responsible for over $6 billion of in-state payroll.
The Massachusetts biopharma industry grew by 42% between between 2002 and 2011.
From the Laboratory to the Factory
Long known as a center for research and development in biotechnology, Massachusetts can count a growing number of manufacturing assets in Massachusetts because of a workforce highly skilled in biologics process development. In addition to a number of contract manufacturers, Massachusetts is also home to commercial manufacturing for Genzyme, Biogen-Idec, AstraZeneca, Abbott Biosciences, Shire, and Pfizer. Bristol-Myers Squibb will complete construction of its largest biologics manufacturing facility in the world at Devens, Massachusetts in 2011. In 2012, Shire's Lexington biologics plant will become the first U.S. plant using disposable manufacturing technologies to receive both EU and FDA approval.